Evoke Pharma announced a patent allowance for GIMOTI® nasal spray, enhancing its protection for treating diabetic gastroparesis.

--Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases with an emphasis on GIMOTI ® nasal spray, today announced that it has ...

Extends patent exclusivity period an additional 6 years once grantedSOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company ...

The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Lupin launches Ipratropium Bromide nasal spray in US, bioequivalent to Atrovent. The product addresses rhinitis and targets a $63 million market opportunity.

About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets ...

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036.

The nasal spray delivery method provides an important alternative for patients with gastroparesis, as the condition can compromise the effectiveness of pills due to slowed gastric absorption.

The company developed, commercialized, and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Intranasal delivery of a monoclonal IgG1 antibody targeting mugwort pollen protected mice from allergic rhinitis and asthma symptoms, without lowering systemic IgE levels. This localized, non-invasive ...